August 23, 2024
Tome Biosciences Halts Operations Amid Financial Strains, CEO Focuses on Strategic Deals
Tome Biosciences, gene editing, layoffs, financial struggles, strategic options, Rahul Kakkar
Semaglutide and Mental Health: A Complex Relationship
semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes
Bicara and Zenas File for IPOs to Advance Late-Phase Cancer and Autoimmune Treatments
Bicara Therapeutics, Zenas BioPharma, IPO, cancer treatment, autoimmune disease, biotech, pharmaceuticals
FDA Approves Updated Covid Vaccines for Fall Season: What You Need to Know
Covid-19 vaccines, FDA approval, updated vaccines, fall season, KP.2 strain, vaccination timing, immunity, side effects.
Jazz Pharmaceuticals’ Epidiolex Fails to Meet Primary Endpoint in Japanese Phase 3 Trial for Treatment-Resistant Epilepsies
Jazz Pharmaceuticals, Epidiolex, Cannabidiol Oral Solution, Treatment-Resistant Epilepsies, Phase 3 Trial, Japan
Bayer Announces 150 Job Cuts in Basel, Switzerland, Amid Global Restructuring
Bayer layoffs, Basel, Switzerland, consumer health hub, job cuts, restructuring
FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications
FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression
Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report
Gene Editing Biotech Tome Scales Back Operations Despite $213M Funding Round
Gene editing, biotech, Tome, funding, investor sentiment, layoffs, reorganization
BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp
BioMarin, executive restructuring, Amgen, Roche, Greg Friberg, James Sabry, Roctavian, hemophilia A gene therapy